AGNC Investment Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AGNC Investment Corp. on June 11, 2021. The filing reports the establishment of a new "at the market" (ATM) equity issuance program and the filing of a new automatic shelf registration statement (Form S-3ASR, No. 333-257014).
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on the authorization of a new capital raising mechanism.
Material Changes
- Termination of Prior Program: The Company's existing "at the market" common stock issuance program under its prior automatic shelf registration statement was terminated on June 11, 2021.
- New ATM Program: The Company implemented a new "at the market" program to offer and sell shares of common stock with an aggregate offering price of up to $1,250,000,000.
- Underwriting Agents: Sales agreements were entered into with ten agents: Goldman Sachs & Co. LLC, BTIG, LLC, Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, J.P. Morgan Securities LLC, JMP Securities LLC, Keefe, Bruyette & Woods, Inc., Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, and Virtu Americas LLC.
- Compensation: Agents are entitled to compensation of up to 1.0% of the gross sales price for shares sold.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the standard terms of the sales agreements. The offering will terminate upon the earlier of the sale of all shares or termination of the Sales Agreements by either party upon 10 days' notice. Sales will be made on a best efforts basis.
Key Facts for Investor Verification
- Verify the total number of shares sold under the new $1.25 billion ATM program in subsequent filings.
- Monitor the Company's cash position and leverage ratios to understand the strategic intent of this equity issuance.
- Review the specific terms of the Sales Agreements (Exhibit 1.1) for any additional covenants or restrictions.
- Check for any concurrent debt issuance or asset sales that may accompany this equity raise.